ABT$102.87

Abbott Laboratories

Last Updated

May 26, 2026about 2 months ago

Moat & Trend

Management

Strong

AI Impact

Competitive Radar

Moat Score

60/100

Executive Summary

Abbott Laboratories has a solid but not exceptional moat built on trusted brands, regulated product portfolios, and embedded positions in diabetes care, diagnostics, and medical devices. FreeStyle Libre, Similac, Ensure, MitraClip, and other platforms give Abbott recurring demand, clinical familiarity, and some switching friction, while global scale helps it compete across more than 160 countries. However, the company lacks meaningful network effects and faces active competition in most categories, from CGMs to diagnostics and infant nutrition. Regulatory scrutiny, product recalls, and litigation can pressure the moat at the margin, but the overall franchise remains durable. We view the moat as narrow rather than wide, with a stable overall trend.

Network Effects

Limited Ecosystem Pull

Pillar Strength

2/10

Abbott has little true network effect. Its core categories are medical devices, diagnostics, and nutrition, where value is created by product performance and clinical trust rather than by a growing user network. The closest analogue is the FreeStyle Libre ecosystem, where apps, cloud data sharing, and patient communities can reinforce adoption, but those benefits are mostly one-way and do not materially increase product utility for other users. Hospitals, physicians, and consumers can multi-home across multiple brands with limited friction. Abbott’s portfolio is better described as an installed-base franchise than a self-reinforcing network. As a result, network effects provide only a thin layer of advantage and are not a major source of durable moat.

Switching Costs

Embedded Clinical Workflows

Pillar Strength

7.5/10

Switching costs are meaningful in several Abbott businesses, especially where devices become embedded in clinical workflows or patient routines. Continuous glucose monitoring users must relearn interfaces, calibrate trust, and often navigate reimbursement or prescription changes when moving to a rival system. In diagnostics, hospitals and labs that validate Abbott platforms like Alinity or i-STAT incur training, integration, and operational disruption if they switch vendors. That said, these costs are real but not prohibitive: competitors offer substitute products, and many purchasing decisions are periodically rebid through payers or procurement teams. Abbott’s switching friction is strongest in chronic-care devices and weakest in commoditized nutrition or rapid tests. Overall, switching costs are a meaningful but not impregnable barrier.

Intangible Assets

Trusted Brands And IP

Pillar Strength

8/10

Abbott’s intangible assets are one of its strongest moat pillars. The company owns highly recognized consumer and medical brands, including Similac, Ensure, Pedialyte, and FreeStyle Libre, that carry trust with parents, clinicians, and patients. In medtech, brand credibility matters because physicians are reluctant to adopt devices with uncertain reliability or safety. Abbott also benefits from patents, regulatory approvals, and proprietary know-how around sensors, delivery systems, and implantable devices, which slow direct imitation. These advantages are strongest in diabetes care and structural heart products, where clinical evidence and reimbursement pathways take years to build. The main weakness is that brand strength varies by segment and can be damaged by recalls or litigation. Even so, this is a durable advantage.

Cost Advantages

Scale Without Dominance

Pillar Strength

6/10

Abbott enjoys some cost advantage from its scale, diversified manufacturing base, and global procurement network, but the edge is only moderate. The company can spread R&D, regulatory, quality, and distribution costs across a large revenue base and multiple product lines, which helps in categories such as diagnostics and nutrition. Its worldwide reach also supports supply-chain flexibility and bargaining power with suppliers and distributors. However, Abbott does not appear to have a structurally superior cost position versus the best competitors in every segment. Many rivals are large, well funded, and capable of matching scale investments in devices, sensors, and tests. Abbott can usually compete efficiently, but it does not consistently enjoy a decisive unit-cost gap that would make cost leadership a primary moat source.

Efficient Scale

Barriers, Not Monopoly

Pillar Strength

6.5/10

Abbott benefits from efficient scale in selected niches, but not across the whole business. Some of its markets are characterized by high regulatory hurdles, clinical evidence requirements, and long commercialization timelines, which limit the number of viable players. Continuous glucose monitoring, implantable cardiac devices, and certain diagnostic systems have features of an oligopoly, where only a few companies can compete credibly at scale. Yet the broader company operates in competitive markets such as nutrition, point-of-care testing, and branded generics, where several rivals can participate. That mix prevents Abbott from looking like a natural monopoly or dominant duopoly overall. Efficient scale therefore supports the moat at the product-line level, but it is not broad enough to transform Abbott into a wide-moat enterprise.

Management Quality Assessment

Evaluating leadership track record, capital allocation, and governance

Verdict

Strong

Robert Ford has led Abbott since 2020 and became chairman in 2021, after rising through medical devices and COO roles, giving the company leadership continuity rather than founder control. Under his tenure Abbott has delivered above-peer shareholder returns, including 2025 TSR of 13% versus a 7% peer median and 3- and 5-year TSR of 21% and 25%. Capital allocation has mixed quality: dividends and buybacks have been steady, but ROIC has slipped to roughly 7%-9%, near WACC and below prior averages, suggesting recent efficiency pressure. Insider ownership appears modest at about 0.5% and trending unclear. Compensation around $24.2M is high, but acceptable given relative outperformance. Governance looks clean, with an 11-of-12 independent board and no obvious related-party red flags.

Key Highlights

Robert Ford has served as CEO since 2020 and chairman since 2021, after previously running Abbott’s medical-device and COO functions. That promotion path suggests operational depth and continuity rather than a disruptive leadership change.
Abbott’s shareholder returns have been strong relative to peers, with 2025 TSR of 13% versus a 7% peer median and 3- and 5-year TSR of 21% and 25%, both above peers.
Capital efficiency has weakened: ROIC has fallen to roughly 7.17%-9.1%, below earlier 3-year and 5-year averages and close to the company’s WACC, indicating less attractive reinvestment economics lately.
Abbott continued returning cash through dividends and buybacks, including about $5 billion returned to shareholders in 2025, while also funding strategic acquisitions to broaden its diagnostics and device franchises.
Governance standards appear solid, with 11 of 12 directors classified as independent and board committees composed exclusively of independent members. Insider ownership is modest at about 0.5% of shares outstanding, but the trend is unclear.

AI Impact Assessment

Evaluating how AI strengthens or disrupts existing moat pillars

AI Opportunity

6/ 10

AI Threat

5/ 10

Net AI Impact

+1Neutral

Net Reinforcer. Abbott’s strongest moat pillars are its installed base in medical devices, recurring diagnostics consumables, and the data generated by FreeStyle Libre, Ultreon, and Alinity. AI can meaningfully improve clinical accuracy, personalization, and workflow, and Abbott’s scale gives it more real-world data than many peers. That said, the near-term effect looks mostly defensive: AI helps preserve switching costs and product differentiation rather than opening a new moat that rivals cannot copy. The facts support active integration and management emphasis on AI; the inference is that this will lift stickiness more than reshape the category. Key uncertainty is whether Abbott can convert proprietary device data into algorithmic advantages before peers such as Roche, Siemens Healthineers, and Medtronic close the gap.

Sign in to see the full analysis

The Strategic Factor Breakdown, Management Quality Assessment, and AI Impact Assessment are available to registered users — it's free.

Last Updated

Apr 5, 20263 months ago

Target Price

Analyst Consensus

Strong Buy17 analysts

FAIR VALUE

Financial Strength

Financial Score

72/100

Executive Summary

Abbott Laboratories exhibits a healthy and well-managed financial profile, notably underpinned by its consistent deleveraging efforts and robust growth in shareholders' equity. While income statement performance has seen some volatility, particularly due to a one-off tax benefit in FY24, operational efficiency remains stable, with projected revenue and EPS growth stabilizing in future years. The balance sheet demonstrates strong asset quality and improving solvency, complemented by solid, though fluctuating, cash flow generation, which supports consistent dividends and share repurchases. Liquidity ratios remain adequate, ensuring comfortable short-term solvency, and profitability metrics, while varied, are generally healthy. Overall, Abbott Laboratories presents a financially sound and resilient profile with controlled debt and a positive growth trajectory, meriting a strong overall assessment.

Income Statement

Revenue · Margins · Profitability

Section Score

7/10

Abbott Laboratories demonstrates a mixed growth trajectory. Revenue showed strong initial growth in FY21, followed by a dip in FY23, and a projected rebound in FY24 and FY25. Net income, however, exhibited volatility, particularly due to an unusual tax benefit in FY24. Gross and operating margins are generally stable, hovering around 55-57% and 16-19% respectively, indicating consistent operational efficiency, typical for a established healthcare company. The significant negative provision for income taxes in FY24, leading to a large spike in net income and profit margin, is a clear one-off event. Excluding this, underlying profitability appears more consistent, albeit with some recent fluctuations. Risks include the lack of sustained, accelerating top-line growth and the reliance on one-time tax benefits for a substantial earnings boost, which can obscure true operational performance. The projected recovery in FY25 margins is a positive signal for future durability.

Financials are in millions USD unless otherwise specified

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	44,328	41,950	40,109	43,653	43,075
Revenue Growth (YoY)	5.67%	4.59%	-8.12%	1.34%	24.46%
Net Income	6,524	13,402	5,723	6,933	7,071
Net Income Growth	-51.32%	134.18%	-17.45%	-1.95%	57.31%
Profit Margin	14.72%	31.95%	14.27%	15.88%	16.42%

Data as of Dec 31, 2025

Balance Sheet

Assets · Liabilities · Equity

Section Score

7.5/10

Abbott Laboratories exhibits a healthy balance sheet with consistent growth in total assets and shareholders' equity. Total assets increased from $75,196 million in FY2021 to $86,713 million in FY2025, driven by rising property, plant & equipment. While total current assets have seen some fluctuation, ending at $25,996 million in FY2025, they remain sufficient relative to total current liabilities of $16,496 million. The company has steadily reduced its total debt from $18,050 million in FY2021 to $12,929 million in FY2025, improving its solvency. Shareholders' equity has shown robust growth, expanding from $36,024 million to $52,771 million over the period, indicating strong asset quality and retained earnings accumulation.

Financials are in millions USD unless otherwise specified

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Current Assets	25,996	23,656	22,670	25,224	24,239
Total Assets	86,713	81,414	73,214	74,438	75,196
Total Current Liabilities	16,496	14,157	13,841	15,489	13,105
Total Liabilities	33,942	33,513	34,387	37,533	39,172

Data as of Dec 31, 2025

Cash Flow Statement

Operations · Investing · Financing

Section Score

7/10

Abbott Laboratories demonstrates generally solid cash generation, with operating cash flow fluctuating but showing an upward trend in the latest two fiscal years, reaching $9,566 million in FY2025. Free cash flow has also rebounded, increasing by 16.44% to $7,395 million in FY2025, indicating sustainable cash after capital expenditures. The company consistently invests in its operations, as reflected by stable capital expenditures around $2.1-2.2 billion annually. Capital allocation prioritizes dividends, with over $4 billion paid out in FY2025, alongside share repurchases, although net debt repayment has varied. While there was notable volatility in operating cash flow in earlier periods, the recent improvements suggest a healthier trajectory, indicating responsible management of its cash resources for both growth and shareholder returns.

Financials are in millions USD unless otherwise specified

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow	9,566	8,558	7,261	9,581	10,533
Operating Cash Flow Growth	11.78%	17.86%	-24.21%	-9.04%	33.31%
Free Cash Flow	7,395	6,351	5,059	7,804	8,648
Free Cash Flow Growth	16.44%	25.54%	-35.17%	-9.76%	51.08%

Data as of Dec 31, 2025

Key Ratios

Liquidity · Leverage · Efficiency · Returns

Section Score

7.5/10

Abbott Laboratories demonstrates solid financial health. Liquidity, as indicated by the current and quick ratios, has generally remained stable, with current ratios consistently above 1.5, suggesting comfort in meeting short-term obligations despite a slight dip in the most recent period. Leverage has been consistently decreasing, with the debt-to-equity ratio falling from 0.48 to 0.19, indicating improved financial risk management. Efficiency metrics show consistent asset turnover around 0.53-0.58, though inventory turnover has slightly declined over the years. Profitability and returns, particularly ROE and ROA, have shown some fluctuation but generally remain healthy. While ROE saw a significant spike in FY2024, it has since settled, suggesting a generally stable but not consistently improving trend. Overall, the company maintains a good financial position with controlled debt and adequate liquidity.

Ratios are dimensionless unless otherwise noted

Metric	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 2, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Debt / Equity Ratio	0.19	0.19	0.26	0.35	0.39	0.48
Quick Ratio	1.18	1.18	1.23	1.16	1.23	1.46
Current Ratio	1.58	1.58	1.67	1.64	1.63	1.85
ROEReturn on Equity (ROE)	12.96%	12.96%	30.91%	15.11%	19.01%	20.49%
ROAReturn on Assets (ROA)	7.38%	7.38%	16.87%	7.54%	9.33%	9.82%
ROICReturn on Invested Capital (ROIC)	9.67%	9.67%	22.29%	10.41%	13.17%	13.36%
ROCEReturn on Capital Employed (ROCE)	11.72%	11.72%	10.78%	10.95%	13.82%	13.73%

Data as of Apr 2, 2026

Growth

Revenue · EPS · Valuation · Estimates

Section Score

7/10

Abbott Laboratories experienced varied historical performance, with strong growth in 2021 followed by declines in 2022 and 2023. Analyst estimates for FY 2024 anticipate a significant EPS rebound (134.36%) on moderate revenue growth (4.59%), suggesting substantial margin expansion. Beyond 2024, revenue growth is projected to be consistent at 5-10%, with EPS growth stabilizing to a more sustainable, positive trend after a projected dip in 2025. Forward P/E ratios for 2026 and 2027 are in the 16-18x range, aligning reasonably with the projected growth rates. Analyst sentiment is strong, with a 'Strong Buy' consensus based on 17 analysts and a tight price target range. The recommendation trend has shown a slight shift from 'Strong Buy' to 'Buy' from March to April 2026, though overall positive conviction remains high.

Analyst Price Targets

Low$120+16.65%

Median$137+33.18%

Average$137.71+33.87%

High$148+43.87%

Strong BuyConsensus rating based on analyst coverage

17 analysts

Recommendation Trends

Rating	Apr '26	Mar '26	Feb '26	Jan '26	Dec '25	Nov '25
Strong Buy	7	7	9	9	9	9
Buy	8	8	8	8	7	7
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	17	17	19	19	18	18

Financial Forecast

Metric	FY 2027	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	52.63B	48.80B	44.33B	41.95B	40.11B	43.65B	43.08B
Revenue Growth	+7.85%	+10.10%	+5.67%	+4.59%	-8.12%	+1.34%	+24.47%
EPS	6.32	5.74	3.72	7.64	3.26	3.91	3.94
EPS Growth	+9.99%	+54.41%	-51.31%	+134.36%	-16.62%	-0.76%	+57.38%
Forward P/E	16.3x	17.9x	—	—	—	—	—

Revenue in USD · EPS per share · Price targets in USD

Data as of FY 2025 · Italic columns are analyst estimates

Fair Value Estimation

P/E · +0.7% Margin of Safety · Fairly Valued

AI Fair Value Estimate (P/E)

$103.62vs$102.87

Margin of Safety+0.7%

Fairly Valued — Trading near intrinsic value

Abbott Laboratories is a stable, profitable company in the healthcare sector with reliable earnings, making the P/E multiple a suitable valuation model. The company's consistent profitability and established market position support the use of earnings-based valuation.

AI Valuation Verdict

Abbott Laboratories is best valued using the P/E multiple due to its stable earnings, established market presence in the healthcare sector, and consistent profitability. We selected Johnson & Johnson, Medtronic, and Thermo Fisher Scientific as comparable companies due to their similar operational profiles and market capitalization within the medical devices and diagnostics industries. Using a blended P/E multiple from these peers and Abbott's trailing EPS, our fair value estimate is 103.62 USD per share, indicating the stock is fairly valued with a marginal upside. The current stock price offers a limited margin of safety. A key sensitivity lies in the selection of comparable companies and their prevailing P/E multiples. A more optimistic market sentiment towards the medical device sector or stronger-than-expected earnings growth could shift the verdict to undervalued. Conversely, any slowdown in growth or sector-specific headwinds could lead to an overvalued assessment. Analyst consensus generally rates ABT as a 'Buy' with a median price target above our fair value, suggesting a more bullish outlook than our current assessment.

Comparable Companies

Company	Ticker	Metric	Multiple	Implied Price
Johnson & Johnson	JNJ	EPS	P/E	$102.39
Medtronic	MDT	EPS	P/E	$96.65
Thermo Fisher Scientific	TMO	EPS	P/E	$111.83

Sign in to see the full analysis

The Income Statement, Balance Sheet, Cash Flow, Key Ratios, Forecast, and Fair Value analysis are available to registered users — it's free.

Sign In to Run AI-Powered Technical Analysis

Create a free account to run a fresh technical analysis across three timeframes — short, medium, and long term.

Disclaimer: The analysis on this page is generated by AI and is provided for informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any security. Always conduct your own due diligence and consult a qualified financial adviser before making any investment decisions.